


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1. **(Previously presented)** A method of treating a host with an angiogenic disease, consisting essentially of contacting said host with a cephalotaxine in an amount sufficient to inhibit angiogenesis associated with said angiogenic disease, wherein said angiogenic disease is not a solid tumor and wherein said angiogenesis associated with said angiogenic disease is inhibited in said host.
2. **(Currently amended)** The method of claim 1 wherein the angiogenic disease is selected from the group consisting of an inflammatory disease, diabetic retinopathy, [[or]] macular degeneration, angiofibroma, neovascular glaucoma, arteriovenous malformation, nonunion fracture, connective tissue disorder, Osler-Weber syndrome, atherosclerotic plaque, psoriasis, ~~eomeal~~ corneal graft neovascularization, Pyogenic granuloma, retrolental fibroplasia, scleroderma, granulations, hemangioma, trachoma, hemophilic joints and vascular adhesions.
3. **(Original)** The method of claim 2 wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, asthma, and pulmonary fibrosis.
4. **(Previously presented)** The method of claim 1 wherein the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methylpentyl) butanedioate ester).
5. **(Previously presented)** The method of claim 1 wherein the cephalotaxine comprises a compound of the formula



wherein R₁ is an ester or an alkyl and wherein R₂ is an ester or an alkyl.

6. **(Currently amended)** The method of claim 1, wherein said contacting is by a route selected from the group consisting of oral, intravenous, topical, ~~intravascular~~ intravesicular, intraperitoneal, intramuscular, intradermal, subcutaneous and intraarterial.

7-14. **(Canceled)**

15. **(Currently amended)** The method of claim 5 ~~or 14~~, wherein said cephalotaxine is selected from the group consisting of harringtonine, isoharringtonine, homoharringtonine, deoxyharringtonine, and acetylcephalotaxine.

16-17. **(Canceled)**

18. **(Currently amended)** The method of claim 2, ~~11 or 16~~ wherein said connective tissue disorder is lupus.

19-22. **(Canceled)**